ESMO Late-breaking Data Show Libtayo® (cemiplimab) and Chemotherapy First-line …
TARRYTOWN, N.Y. and PARIS, Sept. 19, 2021 /PRNewswire/ --. Phase 3 trial met its primary and key secondary endpoints. Libtayo is one of two PD-(L)1 ...
Day: September 19, 2021
ESMO late-breaking data show Libtayo® (cemiplimab) and chemotherapy first-line treatment …
PARIS and TARRYTOWN, N.Y. – September 19, 2021 - Positive Phase 3 results for Sanofi and Regeneron Pharmaceuticals, Inc.'s Libtayo® (cemiplimab) combination ...